LTR Pharma Extends ROXUS Reach Across 43 US States

LTR Pharma has fulfilled more than 500 ROXUS bottles across 43 US states since its 5 October launch, with the first US revenue now received. The company says its prescribing, pharmacy, invoicing and payment infrastructure is operational, although repeat demand remains untested.

  • More than 500 ROXUS bottles fulfilled across 43 US states
  • First US revenue received from October invoicing
  • Surescripts connectivity opens a direct-to-clinic prescribing channel
  • Early feedback cites rapid onset alongside transient nasal irritation
  • Retention and repeat-purchase trends remain immature
An image related to Ltr Pharma Limited A photo of the logo for Ltr Pharma Add us as a preferred source on Google
Image © middle. Logo © respective owner.

ROXUS Reaches 500-Bottle US Milestone

LTR Pharma Limited (ASX:LTP) has moved its US ROXUS rollout from initial fulfilment into the first revenue-generating stage, with more than 500 bottles supplied across 43 states since commercial launch on 5 October. The company said it has invoiced Strive Pharmacy and received payment for October, marking its first US revenue, although it did not disclose the amount.

The geographic spread is notable because ROXUS prescriptions are being fulfilled through state-licensed 503A pharmacies. LTR said the reach reflects both Shed’s telehealth channel, including its Mavrox men’s health platform, and Strive Pharmacy’s licensing footprint. The milestone builds on the first US ROXUS fulfilments reported after quarter-end, when the product had only just begun reaching patients.

Commercial Infrastructure Moves Into Testing

With prescribing, fulfilment, invoicing and payment now operating, LTR has established the basic mechanics of the US launch. But the company is not presenting 500 bottles as evidence of a mature demand curve. Shed is still testing digital marketing, patient acquisition and onboarding while assessing retention and repeat activity before expanding its marketing programme.

That distinction matters for an on-demand treatment, where usage and reorder timing can vary. LTR said the initial patient cohorts have not yet matured enough to provide clear retention or repeat-purchase trends, leaving the quality and durability of demand unresolved.

Specialist Clinics Join the Prescribing Channel

A separate healthcare professional and direct-to-clinic channel is now opening alongside telehealth. LTR has enabled electronic prescribing connectivity through Surescripts and said initial prescribing has begun at a small number of specialist clinics, including practices involving Scientific Advisory Board members Dr Amy Pearlman and Dr Andrew Sun.

The company is initially targeting men’s health, urology and sexual medicine practices with established erectile dysfunction patient populations. Early patient feedback has included reports of rapid onset and positive treatment experiences, while some users have reported short-lived nasal irritation or sneezing. LTR said Australian prescribing experience is being applied to first-use education and administration guidance.

503A Sales Remain Separate From FDA Programme

ROXUS is a compounded intranasal vardenafil formulation prepared for identified individual patients under valid prescriptions through appropriately licensed US pharmacies. It has not been reviewed or approved by the US Food and Drug Administration for safety or efficacy.

That commercial pathway is separate from LTR’s FDA 505(b)(2) development programme for SPONTAN, for which preparations for a planned pivotal Phase III trial continue. The company points to its Phase II pharmacokinetic result, in which SPONTAN 5 mg reached peak blood concentration at a median of 10 minutes versus 60 minutes for a 20 mg oral vardenafil tablet, but the next commercial test is less clinical than operational: whether early fulfilment can become repeat use across both telehealth and specialist channels.

Get ASX:LTP news the moment it breaks

Instant push notifications No waitlist Free
Download on the App Store iPhone & iPad
Get it on Google Play Android
Email alerts

Bottom Line?

The launch has cleared its first operational hurdle, but the more consequential evidence will come from US revenue growth, retention and repeat orders as the initial patient cohorts mature.

Questions in the middle?

  • How much revenue did the first October US orders generate, and what economics remain after partner and pharmacy costs?
  • Will the 500 fulfilled bottles translate into repeat purchasing once the initial patient cohorts mature?
  • Can the direct-to-clinic channel expand beyond the small number of specialist practices now prescribing ROXUS?

Sources

1